AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00523991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation once daily of placebo matching tiotropium via handihaler
Study NCT00009971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Study NCT01142726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
Study NCT01142726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Tablets, oral, 2.5 mg, once weekly, 12 months
Study NCT01142726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept placebo
Description: Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
Study NCT01142726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate placebo
Description: Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
Study NCT03433170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus graft
Description: Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
Study NCT03433170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ST-Gracilis graft
Description: Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study NCT00005059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00005059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01175798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 50,000 IU PO weekly x 6 weeks
Study NCT04600895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir
Study NCT04600895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01681550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Incretin-based therapy
Study NCT03431987 — intervention group
Intervention type: DRUG
Intervention: One day with a dose of placebo cannabis paired with alcohol
Description: Vaporized placebo marijuana with little to no THC paired with drinking alcohol to BrAC of 0.05%
Study NCT03431987 — intervention group
Intervention type: DRUG
Intervention: One day with a dose of active THC cannabis paired with alcohol
Description: Vaporized marijuana with active THC paired with drinking alcohol to BrAC of 0.05%
Study NCT01543087 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sampling
Description: Blood sample collection at different time points
Study NCT01543087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bivalent rLP2086
Description: A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
Study NCT01650090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Lipid Cisplatin (ILC)
Description: ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
Study NCT01290965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet given once or three times daily for 15 consecutive days
Study NCT01290965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCY-635
Description: oral capsule
Study NCT01265771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode
Study NCT01265771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repeated 24 hours ECG Holter monitoring
Description: Repeated 24 hours ECG Holter monitoring
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 10 mg/sqm/day from for 21 days
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: native E-coli Asparaginase 5,000 IU/sqm x 8 doses
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: 30 mg/sqm i.v. 4 doses in Induction phase
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 30 mg/sqm i.v. x 4 doses in Protocol II and III
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/sqm i.v. for 3 doses in HR block 3
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 800 mg/sqm i.v.q12h x 5 in HR block 2
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: 60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigator's choice of platinum agent
Description: Investigator's choice of platinum agent: carboplatin or cisplatin
Study NCT00637949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lumiracoxib
Description: 400 mg once daily, oral over 6 weeks
Study NCT00637949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rofecoxib
Description: 25 mg, oral, daily over 6 weeks
Study NCT02766582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV every 21 days at 200 mg
Study NCT02766582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV every 21 days
Study NCT02766582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion (80mg/m2) every 7 days for 6 cycles
Study NCT03142685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bowel Ultrasound
Description: Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
Study NCT04504851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Description: 10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)
Study NCT04504851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 10mg/kg
Study NCT04504851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 10mg/kg
Study NCT04504851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid 5mg/kg
Study NCT04504851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid 5mg/kg
Study NCT04504851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide 25mg/kg
Study NCT04504851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide 25mg/kg
Study NCT04504851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol 15mg/kg
Study NCT04504851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol 15mg/kg
Study NCT06771557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 656 Online Platform
Description: The 656 Platform provides valuable information regarding three common ailments among the elderly, namely stroke, dementia, and fall-related fractures. Serving as an online platform, the 656 Platform incorporates a Chatbot feature that facilitates connections between local caregivers, social workers, and community members to various services. Serving as an online platform, the 656 Platform incorporates an AI Chatbot and a Live Chat feature that facilitates connections between local caregivers, social workers, and community members to various services. Apart from this, the 656 Platform offers several features that enhance its functionality and user experience, including problem-based elderly resource database, interim care solutions, exchange forum, data analytics and research, and professional knowledge and resources.
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: 60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
Study NCT00613457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: 3 mg/sqm i.v. x 2 doses in HR block 2
Study NCT01017952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Study NCT01017952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 Inhalation Powder
Description: Long Acting Beta Agonist(LABA) Inhalation Powder
Study NCT03804684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard Automatic Perimetry Humphrey Field Analyzer
Description: Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.
Study NCT03804684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: visuALL Field Analyzer
Description: visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.
Study NCT00954278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
Study NCT03598855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Description: Ischemic preconditioning (IPC) refers to cycles of 5 minutes of upper arm cuff inflation with 5 minute periods of cuff deflations, repeated 4 times.
Study NCT01707849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVL arm
Description: Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.
Study NCT01707849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF arm
Description: Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
Study NCT04248738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEEDS
Description: NEEDS intervention includes assessing patients' social needs and resources (SocNSuppR) and communicating those SocNSuppR to discharge teams
Study NCT00809107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Description: 5000IU
Study NCT01472887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR3419
Description: Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous
Study NCT01924208 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Timothy, Phleum pretense
Description: Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
Study NCT01924208 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated influenza virus
Description: Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
Study NCT01924208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timothy + attenuated influenza virus
Description: Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
Study NCT00361634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study NCT04263584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib vials 60 mg
Study NCT04263584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP Chemotherapy
Description: Immunochemotherapy
Study NCT04650451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor (CAR) T cell therapy
Description: HER2-targeted dual-switch CAR-T cells
Study NCT01561898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (JNS007ER)
Description: Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
Study NCT04230252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
Study NCT04329338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus pentosus KCA1
Description: Lactobacillus pentosus KCA1 suspended in dairy and taken orally for 14 days
Study NCT03605628 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: measuring tape
Description: measurement of change in abdominal wall length \[cm\] during neuromuscular block with a measuring tape.
Study NCT03605628 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neuromuscular block
Description: Measurement of the time course of the neuromuscular block: neuromuscular transmission is measured by assessment of the post tetanic count and the train of four ratio using acceleromyography (TOF Watch SX™, Essex Pharma GmbH, Munich, Germany) at the right adductor pollicis muscle with transcutaneous Ag/AgCl electrodes (electrocardiogram electrodes; Ambu Inc., MD 21060 USA);
Study NCT03605628 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surgical rating score
Description: assessment of operating conditions by means of a standardized score: surgical rating score:~1. extremely poor conditions~2. poor conditions~3. acceptable conditions~4. good conditions~5. optimal conditions
Study NCT02646241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unroofing biopsy
Description: Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
Study NCT02646241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)
Description: EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB \& unroofing biopsy.
Study NCT01178658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, etoposide, cytarabine, and melphalan
Description: Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
Study NCT01251783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula
Description: Only Infant Formula without Lactobacillus, Metlin OR Metlos
Study NCT01251783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Exclusively breast milk
Description: Children non randomized which mothers decided to feed them with exclusively breast milk
Study NCT01251783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metlin+metlos+Lactobacillus GG
Description: A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
Study NCT01251783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Metlin + Lactobacillus GG
Description: A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
Study NCT02532699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AC mycelia
Description: An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
Study NCT02532699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
Study NCT03745599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
Study NCT03745599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
Study NCT03745599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzydamine
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.